In comparison to bone marrow, umbilical cord blood has decreased intrinsic immune responsiveness allowing transplantation across HLA barriers with lower rates of graft-versus-host disease. However, laboratory models have also suggested that cord blood may be extremely sensitive to stimulation by cytokines. We report an adult recipient of an ex vivo expanded, HLA-mismatched, unrelated cord blood transplant who experienced a late extramedullary relapse while still in hematologic remission. Despite demonstrating immune tolerance on minimal immunosuppressive agents, a brief course of intravenous interleukin-2 resulted in rapid, aggressive graft-versus-host and graft-versus-leukemia reactions. This case highlights the potential of cytokine immunomodulation following cord blood transplantation, but also suggests caution in stimulating these cells. Bone Marrow Transplantation (2000) 26, 353-355. 
Cord blood stem cells obtained from unrelated individuals may restore hematopoiesis in leukemic patients treated with high-dose chemo-radiotherapy. As a result of 'immunologic immaturity', preliminary reports have suggested that cord blood transplant recipients experience lower rates of graftversus-host disease compared to patients receiving bone marrow, permitting unrelated transplants across HLA barriers. 1, 2 Whether this increased degree of tolerance will yield lower graft-versus-tumor effects and higher rates of late leukemic relapse is yet to be determined. [3] [4] [5] [6] Unlike sibling marrow transplants in which additional infusions of donor lymphocytes may be successful in inciting a graftversus-tumor effect and salvaging relapses, no additional cellular therapy options exist for patients receiving unrelated cord units. Therefore other immunologic salvage maneuvers must be considered. Interleukin-2 has demonstrated anti-tumor activity against acute myeloid leukemia 7 and may augment cytotoxic effects following allogeneic and autologous transplantation. [8] [9] [10] [11] [12] We report a recipient of an unrelated cord blood stem cell transplant who experienced a late extramedullary relapse of leukemia while still demonstrating blood chimerism and apparent tolerance to the graft. Brief exposure to interleukin-2 led to aggressive graft-versus-host and anti-tumor effects. Our experience confirms laboratory models of umbilical cord sensitivity to cytokine stimulation and suggests caution regarding the use of interleukin-2 in these patients.
Case report
A 47-year-old Cuban male underwent an HLA-mismatched, ex vivo expanded, unrelated cord blood stem cell transplant for acute myeloid leukemia, subtype M-1 with normal cytogenetics, in third remission during December 1998. The conditioning regimen consisted of cyclophosphamide 120 mg/kg, total body irradiation 1200 cGy and anti-thymocyte globulin 90 mg/kg. He was rescued by cord blood from an unrelated male child with an unexpanded, unmanipulated total nucleated cell dose of 10 × 10 6 /kg (including 1.26 × 10 5 CD34 cells/kg) on day 0. A second aliquot of cord blood underwent ex vivo expansion using a method developed by Aastrom Biosciences (Ann Arbor, MI, USA). In brief, the cord blood was suspended in tissue culture medium composed of Isocove's modified Dulbecco's medium supplemented with 10% fetal bovine serum, 10% horse serum, hydrocortisone, gentamicin sulfate, PIXY321, erythropoietin, Flt-3 ligand, l-glutamine, and vancomycin. The cells were cultured for 12 days in the Aastrom Replicell System with the tissue culture medium continually replaced by fresh medium. The cells were washed to remove the growth factors and other reagents prior to infusion into the patient on day 12. The total nucleated cell dose of the expanded product was 20 × (mismatches underlined). Graft-versus-host disease prophylaxis consisted of cyclosporin to maintain serum levels between 150 and 250 ng/dl and tapering prednisone doses (maximum prophylactic dose 0.5 mg/kg) to day 100. The patient achieved hematopoietic engraftment with an absolute neutrophil count above 500/l on day 17 and platelets above 50 000 on day 55. His early transplant course was complicated on day 41 by colonoscopy-biopsy documented grade III graft-versus-host disease (Ͼ2 liters of diarrhea per day) which responded to methylprednisolone 2 mg/kg, change from cyclosporin to tacrolimus, and octreotide. The patient developed CMV antigenemia on day 51, which cleared (serial negative CMV antigens including after stopping antiviral therapy) with pre-emptive intravenous ganciclovir therapy to day 96. By day 150 he was doing well, with only minor elevations of hepatocellular enzymes suggestive of chronic graft-versus-host disease. Restaging evaluations at day 133 revealed complete remission with peripheral blood HLA typing converting to donor type (100% chimerism of lymphocyte typing on peripheral blood specimens) and red cell blood type converting to donor type, allowing removal of all steroids by day 133, and initiation of a planned slow taper of tacrolimus. On day 195 following transplant, while on only tacrolimus 2 mg/day and prophylactic antibiotics including acyclovir, he developed diffuse subcutaneous nodules. On biopsy these revealed relapse of myeloid leukemia with histologic features similar to the original tumor (AML subtype M1). Interestingly his peripheral blood counts remained stable, his HLA typing again confirmed donor lymphocyte phenotype and there was no evidence of graft-versus-host disease. For treatment of the extramedullary leukemic relapse he was given interleukin-2 nine million units/m 2 daily by continuous intravenous infusion for 4 consecutive days. 13 By the 4th treatment day he had developed oral ulcerations and by the 6th day he had hyperbillirubinemia (4.9 mg/dl). By the 7th day he developed diffuse pruritic erythroderma with blisters and by the 10th day he had profuse diarrhea consistent with grade IV GVHD (skin 4, gut 3, liver 2). Treatment with methylprednisolone 2 mg/kg, tacrolimus to maintain serum levels 10-20 ng/dl, and anti-thymocyte globulin 160 mg/kg i.v. (administered over 4 days) stabilized the patient. Concurrent with the GVHD the patient's diffuse subcutaneous leukemic nodules rapidly resolved. Upon treatment of the GVHD his skin had no visual evidence of residual leukemia and his blood counts returned to normal ranges supporting a fourth remission state. Although interleukin-2 may have direct favorable effects on leukemia, the rapidity of the leukemic improvement and the aggressiveness of the graft-versus-host reactions suggested an immunologic response as the primary anti-tumor mechanism. He unfortunately developed recurrent diarrhea 1 month after the GVHD episode. CMV antigens in the peripheral blood were noted on day 222 and colonoscopy revealed CMV colitis, which failed to respond to ganciclovir therapy.
Discussion
The establishment of large banks of unrelated umbilical cord blood stem cell units is allowing high-dose therapy to be offered to individuals lacking sibling donors. Functional characterization of primitive cells in cord blood has revealed their extensive proliferative capacity, but differing responses to cytokines compared to bone marrow or peripheral blood stem cells. 3 A decrease in the capacity of cord blood to generate cytotoxic T lymphocytes, a decrease in secondary alloresponsiveness, changes in ras intracellular signal transduction, lower levels of CD8 + interferon-gamma secretion, and a shift towards type T2 response of CD4 lymphocytes, compared to adult bone marrow, may partially explain the lower rates of graft-versus-host disease noted in clinical series. 3, 6 Whether these beneficial effects of downregulating graft-versus-host disease will also impair graft-versus-tumor effects remains unknown, although early clinical results have not suggested excessive relapses.
Laboratory models have suggested that cord blood stem cells may be more sensitive to exogenous interleukin-2 stimulation than adult marrow cells. Incubation experiments have noted increased anti-tumor effects against K562 cells compared to marrow cells. 5, 14 NK activity of cord blood, which may be important in the graft-versus-tumor effect, is also enhanced by interleukin-2 and interleukin-12.
15 Although unstimulated NK cell activity appears similar in cord and bone marrow, LAK cells from umbilical cord blood may have a significantly greater ability to kill target cells by necrosis-mediated cytotoxicity and apoptotic-mediated cytotoxicity. Interleukin-2 also induces significantly greater granzyme B activity in cord blood cells compared to bone marrow. 16 Experimental mouse models of cord blood transplantation, which confirm weaker graftversus-leukemia effects, have demonstrated greatly enhanced anti-tumor effects with delayed donor T lymphocyte infusion suggesting that adoptive immunotherapy strategies may be more potent after cord blood transplantation compared to bone marrow transplantation. Interleukin-2 may have direct anti-leukemic effects and has been used to salvage relapsed acute myeloid leukemia. In one series, 13 of 24 patients obtained a complete response to interleukin-2 therapy without additional cytotoxic chemotherapy. 11 Therefore, in the absence of cellular immunotherapy options such as donor lymphocytes, we reasoned that a therapeutic trial of interleukin-2 might be appropriate in our cord blood recipient. Although interleukin-2 therapy has been used to consolidate remission states following autologous transplants and has been used in conjunction with donor lymphocyte infusions, there is limited experience for interleukin-2 therapy following allogeneic transplantation. 13 A phase I dose escalation immunotherapy consolidation trial enrolled children beyond first remission with AML who underwent HLA-identical sibling transplants. Beginning a median of 68 days after transplant, interleukin-2 (at doses up to 3 million IU /m 2 /day for five days followed by a low dose maintenance dose) appeared well tolerated without inducing significant acute (12%) or chronic graft-versus-host disease (31%, most occurring at doses of 6 million units/m 2 /day). Lymphocytosis, with an increase in CD56 + and CD8 + cells, was noted. 9 Following T cell-depleted transplants, prolonged infusions of low-dose interleukin-2 at doses 200 000-400 000 units/m 2 /day were tolerated for up to 3 months, without significant acute graftversus-host disease (3%). After 12 weeks of treatment the mean number of circulating NK cells increased 10-fold, without any significant increase in T cell number. 17 Interleukin-2 has also been utilized to augment the effects of cellular immunotherapy. One trial successfully reinduced 10 of 17 patients who had leukemic recurrence following allogeneic transplantation, with four responding to donor lymphocytes alone, but six additional responses after activation by interleukin-2. 8 Our patient, who underwent unrelated HLA-mismatched umbilical cord blood stem cell transplantation, was able to achieve hematopoietic chimerism and a state of tolerance without ongoing graft-versus-host disease. Unfortunately, he developed a late extramedullary skin relapse while maintaining peripheral blood evidence of remission. A brief course of interleukin-2 induced early, aggressive graftversus-host and graft-versus-leukemia responses. These reactions were consistent with the above laboratory models suggesting increased responsiveness of cord blood stem cells to exogenous cytokines. Our clinical experience demonstrated that immunodulatory agents might have a role in the treatment of relapse following cord blood transplantation, where cellular options do not exist, but also suggests that caution is necessary.
